From Algae to Neural Circuits: What the 2026 Medicine Nobel Means for Optogenetics
Dr. Dereck Mush, MD, MBA
ImpriMed
Live-cell testing and multimodal AI for precision oncology and drug-development decisions.
What they do
ImpriMed combines ex vivo assays of patient-derived cancer cells with genomic, immunophenotypic and clinical data. Its $10 million Series A2 bridge, led by LB Investment, supports US commercialization and expansion in Asia.
The record
- Vertical
- Oncology
- Sub-segment
- Functional precision medicine
- Product type
- Diagnostics
- Stage
- Series A
- Headquarters
- Palo Alto, CA, USA
- Region
- North America
- Founded
- 2017
- Total funding
- $33M raised
Notable investors: LB Investment, NAVER D2SF, Samsung Securities, Alois Ventures.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
Molecular Cardioprotection: How Pediatric Myosin Inhibition Redefines the Economics of Congenital Heart Care
Dr. Dereck Mush, MD, MBA
Overcoming the Solvent Front: How Jideytro Validates Nuvalent's Precision Oncology Playbook
Dr. Dereck Mush, MD, MBA
Beyond PD-L1: How the I3LUNG Consortium Validated Multimodal AI in 2,365 Advanced Lung Cancer Patients
Dr. Dereck Mush, MD, MBA